Inducible nitric oxide synthase gene and diabetic retinopathy in Asian Indian patients

Clinical Genetics

Volumn 61, Issue 5, 2002, Pages 344-348

  Kumaramanickavel, G ^a   Sripriya, S ^a   Vellanki, R N ^a   Upadyay, N K ^b   Badrinath, S S ^b   Rajendran, V ^a   Sukumar, B ^b   Ramprasad, V L ^a   Sharma, T ^b  

^a VISION RESEARCH FOUNDATION   (India)

^b MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

Allelic polymorphism; Diabetic retinopathy; Inducible nitric oxide synthase gene; Type 2 diabetes

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ALLELE; ARTICLE; ASIAN; CONTROLLED STUDY; DIABETIC RETINOPATHY; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INDIAN; IRELAND; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE REPEAT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE;

ALLELES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYMORPHISM, GENETIC;

EID: 0036590214     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0009-9163.2002.00251.x     Document Type: Article

References (51)

1. Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997: 350 (Suppl): 9-13.
2. Warpeha KM, Xu W, Liu L et al. Genotyping and functional analysis of a polymorphic (CCTTT) (n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999: 13: 1825-1832.
3. The Diabetes Control and Complications Trial Research Group. Clustering of long term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997: 46: 1829-1839.
4. Sheng H, Ignarro LJ. Biochemical and immunohistochemical characterization of nitric oxide synthase in rat retina. Pharmacol Res 1996: 33: 29-34.
5. Goldstein IM, Ostwald P, Roth S. Nitric oxide: a review of its role in retinal function and disease. Vis Res 1996: 36: 2979-2994.
6. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991: 43: 109-142.
7. Yilmaz G, Esser P, Kociek N, Aydin P, Heimann K. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2000: 130: 87-90.
8. Vallance P, Collier J. Biology and clinical relevance of nitric oxide. Br Med J 1994: 309: 453-457.
9. Lincoln J, Hoyle CHV, Burnstock G. Nitric Oxide in Health and Disease. Cambridge University Press, 1997.
10. Yoshida A, Pozdnyakov N, Dang L, Orselli SM, Reddy VN, Sitaramayya A. Nitric oxide synthesis in retinal photoreceptor cells. Vis Neurosci 1995: 12: 493-500.
11. Yamamoto R, Bredt DS, Snyder SH, Stone RA. The localization of nitric oxide synthase in the rat eye and related cranial ganglia. Neuroscience 1993: 54: 189-200.
12. Chakravarthy U, Stitt AW, McNally J, Bailie JR, Hoey EM, Duprex P. Nitric oxide synthase activity and expression in retinal capillary endothelial cells and pericytes. Curr Eye Res 1995: 14: 285-294.
13. Becquet F, Courtois Y, Goureau O. Nitric oxide decreases in vitro phagocytosis of photoreceptor outer segments by bovine retinal pigmented epithelial cells. J Cell Physiol 1994: 159: 259-262.
14. Dighiero P, Reux I, Hauw JJ, Fillet AM, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in cytomegalovirus-infected glial cells of retinas from AIDS patients. Neurosci Lett 1994: 166: 31-34.
15. Goureau O, Hicks D, Courtois Y, De Kozak Y. Induction and regulation of nitric oxide synthase in retinal Muller glial cells. J Neurochem 1994: 63: 310-317.
16. Goureau O, Bellot J, Thillaye B, Courtois Y, de Kozak Y. Increased nitric oxide production in endotoxin-induced uveitis. Reduction of uveitis by an inhibitor of nitric oxide synthase. J Immunol 1995: 154: 6518-6523.
17. Jacquemin E, de Kozak Y, Thillaye B, Courtois Y, Goureau O. Expression of inducible nitric oxide synthase in the eye from endotoxin-induced uveitis rats. Invest Ophthalmol Vis Sci 1996: 37: 1187-1196.
18. Tilton RG, Chang K, Corbett JA et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994: 35: 3278-3288.
19. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol 1997: 42: 71-82.
20. Ziche M. Role of nitric oxide in the angiogenesis of avascular tissue. Osteoarthritis Cartilage 1999: 7: 403-405.
21. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993: 329: 2002-2012.
22. Calver A, Collier J, Vallance P. Nitric oxide and cardiovascular control. Exp Physiol 1993: 78: 303-326.
23. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993: 341: 465-466.
24. Boughton-Smith NK, Evans SM, Hawkey CJ et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993: 342: 338-340.
25. de Belder AJ, Radomski MW, Why HJ et al. Nitric oxide synthase activity in human myocardium. Lancet 1993: 341: 84-85.
26. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991: 338: 1557-1558.
27. Xu W, Liu LZ, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997: 204: 165-170.
28. Johannesen J, Tarnow L, Parving HH, Nerup J, Pociot F. CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2000 23 (4): 560-562.
29. Hawrami K, Hitman GA, Rema M et al. An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hum Immunol 1996: 46: 49-54.
30. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000: 41: 4064-4068.
31. Wolff R, Gemmil R. Purifying and analysing genomic DNA. In: Birren B, Green ED, Myers RM, Roskams J, eds. Genome Analysis: A Laboratory Manual, Vol. 1. USA: Cold Spring Harbour Press, 1998: 1-82.
32. Sambrook J, Fritsch EF, Manniatis T. Gel electrophoresis. In: Ford N, Nolan C, Ferguson M, eds. Molecular Cloning: A Laboratory Manual. USA: Cold Spring Harbour Press, 1997: 173-178.
33. Dandona L, Dandona R, Naduvilath TJ, McCarty CA, Rao GN. Population based assessment of diabetic retinopathy in an urban population in southern India. Br J Ophthalmol 1999: 83: 937-940.
34. Michaelson I. The mode of development of the vascular system of the retina with some observation for its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948: 68: 137-186.
35. Shinoda K, Ishida S, Kawashima S et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial. growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol 1999: 83: 834-837.
36. Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 1992: 114: 731-736.
37. Franks WA, Limb GA, Stanford MR et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992: 11 (Suppl): 187-191.
38. Kumaramanickavel G, Sripriya S, Vellanki RN et al. Tumor necrosis factor allelic polymorphism and non-insulin-dependent diabetes mellitus retinopathy. Diabetes Res Clin Pract 2001: 54: 89-94.
39. Goureau O, Hicks D, Courtois Y. Human retinal pigment epithelial cells produce nitric oxide in response to cytokines. Biochem Biophys Res Commun 1994: 198: 120-126.
40. Goureau O, Lepoivre M, Becquet F, Courtois Y. Differential regulation of inducible nitric oxide synthase by fibroblast growth factors and transforming growth factor beta in bovine retinal pigmented epithelial cells: inverse correlation with cellular proliferation. Proc Natl Acad Sci U S A 1993: 90: 4276-4280.
41. Goureau O, Lepoivre M, Courtois Y. Lipopolysaccharide and cytokines induce a macrophage-type of nitric oxide synthase in bovine retina pigmented epithelial cells. Biochem Biophys Res Commun 1992: 186: 854-859.
42. do Carmo A, Lopes C, Santos M, Proenca R, Cunha-Vaz J, Carvalho AP. Nitric oxide synthase activity and L- arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen Pharmacol 1998: 30: 319-324.
43. Hattenbach LO, Allers A, Klais C, Koch F, Hecker ML. Arginine-nitric oxide pathway-related metabolites in the aqueous humor of diabetic patients. Invest Ophthalmol Vis Sci 2000: 41: 213-217.
44. Martin AR, Bailie JR, Robson T et al. Retinal pericytes control expression of nitric oxide synthase and endothelin-1 in microvascular endothelial cells. Microvasc Res 2000: 59: 131-139.
45. Schmetterer L, Findl O, Fasching P et al. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes 1997: 46: 653-658.
46. Roth S. Role of nitric oxide in retinal cell death. Clin Neurosci 1997: 4: 216-223.
47. Hangai M, Yoshimura N, Hiroi K, Mandai M, Honda Y. Inducible nitric oxide synthase in retinal ischemia-reperfusion injury. Exp Eye Res 1996: 3: 501-509.
48. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991: 88: 11555-11558.
49. Misko, TP, Moore WM, Kasten TP et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993: 233: 119-125.
50. Tilton RG, Chang K, Hasan KS et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993: 42: 221-232.
51. Corbett JA, Tilton RG, Chang K et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992: 41: 552-556.